How to Reconstitute Tirzepatide for In Vitro Research: Laboratory Protocol
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
How to Reconstitute Tirzepatide for In Vitro Research: Laboratory Protocol
Tirzepatide (MW 4813.5 g/mol) is a synthetic 39-amino acid dual GIP-R/GLP-1R agonist incorporating a C20 fatty diacid modification at Lys20 that enables albumin binding. It is supplied as a lyophilised white powder in a 10mL sterile glass vial containing 5mg of peptide. As a dual incretin receptor research compound, tirzepatide requires careful reconstitution technique to preserve the integrity of both the GIP-mimetic N-terminal pharmacophore and the GLP-1R-active C-terminal sequence.
Materials Required
- Tirzepatide 5mg lyophilised vial
- Bacteriostatic water (BAC water) — 10mL vial
- 1mL sterile syringe with needle
- Alcohol swabs (70% isopropyl)
- Nitrile gloves
- Permanent marker for labelling
- Refrigerator at 2–8°C for storage
Pre-Reconstitution Preparation
Inspect the vial to confirm the lyophilised powder is intact and the seal is unbroken. Remove from cold storage and allow to equilibrate to room temperature for 15–20 minutes before reconstitution. Tirzepatide's large molecular weight (4813.5 g/mol) and C20 fatty acid modification make it one of the more hydrophobic peptides in the research category — adequate room temperature equilibration is important to ensure even solvent distribution across the powder surface during dissolution.
Step-by-Step Reconstitution Protocol
Step 1 — Prepare workspace. Wipe the work surface with 70% isopropyl alcohol and allow to dry. Use nitrile gloves throughout the procedure.
Step 2 — Swab both stoppers. Clean rubber stoppers on both vials with separate fresh alcohol swabs. Allow to air dry for 10–15 seconds.
Step 3 — Draw 2mL of BAC water. Draw 2mL of bacteriostatic water into a sterile syringe.
Step 4 — Inject very slowly along the vial wall. Insert the needle at an angle against the inner glass wall of the tirzepatide vial and inject the BAC water in a very slow, thin stream over 20–25 seconds. Tirzepatide's fatty acid modification makes it more prone to foaming than smaller unmodified peptides — slow, wall-directed injection is especially important here to prevent foam formation that can reduce peptide recovery from the vial.
Step 5 — Dissolve by gentle rolling. Roll the vial slowly between your palms and swirl gently for 60–120 seconds. Tirzepatide may require up to 2 minutes of gentle swirling to dissolve fully at 2.5mg/mL. The solution should become clear to very slightly opalescent — a mild opalescence is normal due to albumin-interaction properties and does not indicate incomplete dissolution. Do not shake or vortex.
Step 6 — Inspect and label. Confirm the solution is clear with no visible particles. Label with reconstitution date, concentration, and initials.
Resulting Concentration
Adding 2mL BAC water to a 5mg tirzepatide vial yields a stock concentration of 2.5mg/mL (2500mcg/mL). For GIP-R and GLP-1R receptor pharmacology studies in HEK293-hGIP-R, HEK293-hGLP-1R, or INS-1 beta-cell model preparations, working concentrations of 0.1nM–1µM are prepared by serial dilution into assay buffer or serum-free media immediately before assay.
Concentration Reference Table
| BAC Water Volume Added | Resulting Concentration |
|---|---|
| 1mL | 5.0mg/mL (5000mcg/mL) |
| 2mL | 2.5mg/mL (2500mcg/mL) |
| 5mL | 1.0mg/mL (1000mcg/mL) |
Storage Conditions and Stability
Store lyophilised tirzepatide at −20°C prior to reconstitution, protected from light. Once reconstituted, store at 2–8°C. Reconstituted tirzepatide in BAC water is stable for up to 28 days under refrigeration. Do not freeze reconstituted solution. Avoid buffers or media containing free thiols (DTT, beta-ME) as these may interact with the fatty acid linker chemistry. For long-term working aliquot storage, freeze single-use aliquots at −80°C.
Research Application Notes
As with semaglutide, tirzepatide's C20 fatty acid modification produces albumin binding in serum-containing cell culture media, reducing the free peptide concentration available for GIP-R and GLP-1R engagement. For precise incretin receptor pharmacology studies, use serum-free or BSA-free media conditions, or calculate free tirzepatide fraction using equilibrium dialysis data. In dual receptor pharmacology studies, include receptor-selective antagonists — GIP(3-30)NH2 at 1µM for GIP-R and exendin(9-39) at 1µM for GLP-1R — to dissect individual receptor contributions to tirzepatide's composite signalling responses in co-expressing cell model systems. Tirzepatide 5mg vials are available from Pinnacle Peptides, verified at ≥99% purity by HPLC and mass spectrometry.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
